Ludwig Enterprises Inc LUDG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LUDG is a good fit for your portfolio.
News
-
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
-
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
-
Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers
-
Ludwig Enterprises mRNA Bladder Cancer Study to be Launched
Trading Information
- Previous Close Price
- $0.23
- Day Range
- $0.25–0.25
- 52-Week Range
- $0.06–0.52
- Bid/Ask
- $0.20 / $0.29
- Market Cap
- $38.96 Mil
- Volume/Avg
- 100 / 11,898
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- —
- Total Number of Employees
- 2
- Website
- https://www.ludwigent.com
Valuation
|
Metric
|
LUDG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LUDG
|
|---|---|
Quick Ratio | 0.07 |
Current Ratio | 0.07 |
Interest Coverage | −4.06 |
Quick Ratio
LUDG
Profitability
|
Metric
|
LUDG
|
|---|---|
Return on Assets (Normalized) | −1,152.54% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,726.34% |
Return on Assets
LUDG
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Blfbmfm | Frkmyg | $182.7 Bil | |
SYK
| Stryker Corp | Srggydnsr | Sqsc | $124.6 Bil | |
MDT
| Medtronic PLC | Fyvprwwr | Vzpzwy | $105.2 Bil | |
BSX
| Boston Scientific Corp | Vwfcbwb | Njchw | $99.1 Bil | |
EW
| Edwards Lifesciences Corp | Gwkfpptg | Ygwksm | $52.0 Bil | |
DXCM
| DexCom Inc | Ysyzkgfcv | Tnsdp | $51.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Kzwymhrwjx | Mpdp | $24.5 Bil | |
ALGN
| Align Technology Inc | Stvrjqgcx | Vhbbqyc | $22.7 Bil | |
PHG
| Koninklijke Philips NV ADR | Twvyjbdf | Lbjjhk | $18.3 Bil | |
PODD
| Insulet Corp | Kqylmhrkrc | Vqzmlfk | $11.6 Bil |